Journal article
Manipulating melatonin in managing mood
P Boyce, M Hopwood
Acta Psychiatrica Scandinavica | Published : 2013
DOI: 10.1111/acps.12175
Abstract
Objective: Disturbances in circadian rhythms have been associated with major depression and may be an underlying mechanism for the disorder. Resynchronisation of circadian rhythms may provide a new approach to treatment, especially by manipulating melatonin secretion. Melatonin is secreted at night and is a stable marker of circadian rhythms. The timing of its secretion can be changed by exogenous melatonin, agonism of specific melatonin receptors in the suprachiasmatic nucleus, its suppression by light and by sleep deprivation. Method: As part of a series of papers ['Chronobiology of mood disorders' Malhi & Kuiper. Acta Psychiatr Scand 2013;128 (Suppl. 444): 2-15; and 'Getting depression cl..
View full abstractGrants
Funding Acknowledgements
[ "Professor Philip Boyce has served on a number of international and national pharmaceutical advisory boards, received funding for research and has been in receipt of honoraria for talks at sponsored meetings worldwide involving the following companies: Servier, AstraZeneca, Eli Lilly, Janssen, Lundbeck, Brain Resource Company.", "Professor Malcolm Hopwood has served on a number of international and national pharmaceutical advisory boards, received funding for research and travel support and has been in receipt of honoraria for talks at sponsored meetings worldwide involving the following companies: Astra-Zeneca, Boehringer, Bristol-Myers-Squibb, Eli-Lilly, Janssen-Cilag, Lundbeck, Pfizer, Schering Plough, Servier, Wyeth, Medimark international, Lifeblood, MD Briefcase, Summer Foundation, Wintringham, Sanofi-Aventis, AHMRF, Cephalon, Forrest, GSK, Sunovion, VNI, Weary Dunlop Foundation." ]